Literature DB >> 15125565

[Pyrido [3,2-b]indol-4-yl-amines--synthesis and investigation of activity against malaria].

K Görlitzer1, C Kramer, H Meyer, R D Walter, H Jomaa, J Wiesner.   

Abstract

Pyrido[3,2-b]indol-4-yl-amines--synthesis and investigation of activity against malaria Starting with 3-aminoindole-2-carboxylic acid ester 1 the annulated pyrido[3,2-b]indoles 6 and 8 were synthesized as key substances. The 4-chloropyridine derivative 8 reacted with the phenol Mannich bases 11 and the novaldiamine base 13, respectively, to yield the amodiaquine and cycloquine analogues 12 as well as the chloroquine analogue 14. The stability of the compounds 12 and 14 were proven by the half wave potentials measured by differential pulse voltammetry. Compounds 12 and 14 were tested for in vitro antimalarial activity using a chloroquine sensitive and a chloroquine resistant Plasmodium falciparum strain. The highest activity was shown by 12g with IC50 values of 50 nM and 38 nM, respectively. The in vivo activity of 12g was tested in Plasmodium vinckei infected mice resulting in ED50 values of 22 mg/kg and 26 mg/kg after intraperitoneal and oral administration, respectively.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15125565

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  3 in total

1.  Why do some Fischer indolizations fail?

Authors:  Nihan Çelebi-Ölçüm; Ben W Boal; Alexander D Huters; Neil K Garg; K N Houk
Journal:  J Am Chem Soc       Date:  2011-03-28       Impact factor: 15.419

Review 2.  Mannich bases in medicinal chemistry and drug design.

Authors:  Gheorghe Roman
Journal:  Eur J Med Chem       Date:  2014-10-30       Impact factor: 6.514

3.  Synthesis of novel indolo[3,2-c]isoquinoline derivatives bearing pyrimidine, piperazine rings and their biological evaluation and docking studies against COVID-19 virus main protease.

Authors:  Vaijinath A Verma; Anand R Saundane; Rajkumar S Meti; Dushyanth R Vennapu
Journal:  J Mol Struct       Date:  2020-12-27       Impact factor: 3.196

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.